ClinicalTrials.gg
Not yet recruitingNCT07533318Updated Apr 16, 2026

A Study of Endocrine, Metabolic, and Genetic Risk Factors of Pediatric Persistent Hypoglycemia at Sohag University Hospital

An observational study in Hypoglycaemia, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
50
Ages
1 Day to 18 Years
Sex
All
01

Study summary

Glucose is the key metabolic substrate for tissue energy production. In the perinatal period, the mother supplies glucose to the fetus, and for most of the gestational period, the normal lower limit of fetal glucose concentration is around 54 mg/dl (3 mmol/L)(1). During the first 24-48 hours of life, as normal neonates transition from intrauterine to extrauterine life, their plasma glucose (PG) concentrations are typically lower than later in life (2). Distinguishing between transitional neonatal glucose regulation in normal newborns and hypoglycemia that persists or occurs for the first time beyond the first 3 days of life is important for prompt diagnosis and effective treatment to avoid serious consequences, including seizures and permanent brain injury (2) The definition of hypoglycemia remains controversial in neonates and children. Some approaches define hypoglycemia on the basis of symptoms, others on the PG value. According to the American Academy of Pediatrics (AAP) and Pediatric Endocrine Society (PES), hypoglycemia is diagnosed when plasma glucose is, respectively, \<47 mg/dL and \<50 mg/dL in at term newborns during the first 48 h of life. Different threshold values have been proposed for pre-term infants (3,4) .

In at-term newborns after the first 48 h of life, infants and younger children, hypoglycemia is defined when plasma glucose is \<50 mg/dL. This threshold value is low enough to avoid false-positive results, but is unlikely to lead to permanent neurological damage. In older children, it is possible to use Whipple's triad characterized by signs and/or symptoms of hypoglycemia, reduced plasma glucose concentration and resolution of these signs/symptoms after acquisition of normoglycemic status(3,4). Per the AAP guidelines, if it is not possible to maintain a glucose concentration >45 mg/dL after 24 hours with using a glucose infusion rate (GIR) rate of 5-8 mg/kg/min, consideration should be given to the possibility of a disorder causing persistent hypoglycemia (5,6) Also, Persistent hypoglycemia (PH) beyond 3 days of life warrants investigation. (7) Blood glucose concentrations are maintained within this range by a complex interplay of hormones that control glucose production and utilization. The key hormones that regulate glucose homeostasis include insulin, glucagon, epinephrine, norepinephrine, cortisol, and growth hormone. Pathological endocrine and metabolic conditions that affect either glucose production or utilization can lead to hypoglycemia (8) The most common causes of hypoglycemia in children are diabetes and idiopathic ketotic hypoglycemia. Hypoglycemia also occurs in other endocrine disorders and inborn errors of metabolism (IEMs). In most cases, hypoglycemia is due to increased usage of glucose (hyperinsulinism, fatty acid oxidation disorders (FAODs), sepsis), decreased nutritional supply (gastroenteritis), or decreased endogenous production of glucose (adrenal insufficiency, IEMs, liver failure) (8). The primary endocrine cause of persistent neonatal hypoglycemia is hyperinsulinism (HI), where dysregulated insulin secretion suppresses ketone production and deprives the brain of alternative fuels. HI can be genetic, such as mutations in the KATP channel genes, or acquired due to perinatal stress factors like intrauterine growth restriction. Hormone deficiencies, including hypopituitarism with cortisol and growth hormone deficiency, can also present with hypoglycemia in the newborn period (4). Metabolic disorders causing hypoglycemia include fatty acid oxidation disorders, which prevent fat breakdown and result in hypoketotic hypoglycemia with potential liver or cardiac involvement. Glycogen storage diseases impair glucose release from glycogen stores and gluconeogenesis, leading to severe fasting hypoglycemia accompanied by elevated lactate and hepatomegaly. Disorders of gluconeogenesis similarly disrupt the liver's ability to convert substrates like alanine and glycerol into glucose (4). Genetic causes of hypoglycemia in children include monogenic defects such as mutations in ABCC8 and KCNJ11 causing congenital hyperinsulinism, as well as genes involved in glycogen storage diseases (e.g., G6PC, PYGL), gluconeogenesis (e.g., FBP1), and hormonal regulation (e.g., GLUD1, HNF4A). Advances in next- generation sequencing have enabled the identification of both common and rare genetic etiologies, improving diagnostic accuracy and personalized management (4).

Retrospective studies suggest the rate of undiagnosed endocrine or metabolic disorders in pediatric patients with recurrent hypoglycemia is as high as 8-28% (9,10) In our study, we will use a stepwise approach to help early and accurate diagnosis of endocrine, metabolic, and suspected genetic causes of persistent hypoglycemiaamong children at Sohag University Hospital.

02

Conditions studied

  • Hypoglycaemia

Browse trials for

03

In context

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

This study's planned enrollment of 50 is below the median of 86 across 131 observational studies indexed under Hypoglycemia.

Browse Hypoglycemia studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients from birth up to 18 years of life, presented with persistent and recurrent hypoglycemia, will be included in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients from birth up to 18 years of life who presented with persistent and recurrent hypoglycemia, will be included in the study Persistent hypoglycemia (PH) is that persist beyond 3 days or Per the AAP guidelines, if it is not possible to maintain a glucose concentration >45 mg/dL after 24 hours with using a GIR rate of 5-8 mg/kg/min (5,6) Recurrent hypoglycemia is the occurrence of more than 2 episodes of low blood sugar, often associated with symptomatic neuroglycopenia.

Exclusion criteria

Exclusion Criteria:

  • Transient hypoglycemia:e.g Neonate:e.g

    1. Infant of a diabetic mother
    2. Prematurity
    3. Intra-uterine growth retardation
    4. Perinatal stress ( infection/sepsis, asphyxia, hypothermia, and respiratory distress)
    5. Maternal beta blocker use Infant and Childhood:e.g

    <!-- -->

    1. Malnutrition (marasmus or kwashiorkor)
    2. Illness ( gastroenteritis, vomiting, or diarrhea leading to inadequate intake )
    3. Prolonged exercise/fasting
    4. Diabetic patient on insulin therapy
    5. Medications/ toxins: accidental ingestion of diabetes medication, alcohol, or aspirin
    6. Factitious hypoglycemia
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Diagnosis of neonates, infants, and children with endocrine, metabolic, and suspected genetic causes of persistent hypoglycemia at Sohag University Hospital.

    Time frame: 2 years

07

Study locations

1 site
  • Pediatric department, Sohag University Hospital
    Sohag, Sohag Governorate 82524, Egypt
08

References and documents

Publications

  • Rosenfeld E, Alzahrani O, De Leon DD. Undiagnosed hypoglycaemia disorders in children detected when hypoglycaemia occurs in the setting of illness: a retrospective study. BMJ Paediatr Open. 2023 Feb;7(1):e001842. doi: 10.1136/bmjpo-2022-001842. PubMed 36759017 ↗
  • White K, Truong L, Aaron K, Mushtaq N, Thornton PS. The Incidence and Etiology of Previously Undiagnosed Hypoglycemic Disorders in the Emergency Department. Pediatr Emerg Care. 2020 Jul;36(7):322-326. doi: 10.1097/PEC.0000000000001634. PubMed 30365409 ↗
  • Ghosh A, Banerjee I, Morris AAM. Recognition, assessment and management of hypoglycaemia in childhood. Arch Dis Child. 2016 Jun;101(6):575-580. doi: 10.1136/archdischild-2015-308337. Epub 2015 Dec 30. PubMed 26718813 ↗
  • Mehta S, Brar PC. Severe, persistent neonatal hypoglycemia as a presenting feature in patients with congenital hypopituitarism: a review of our case series. J Pediatr Endocrinol Metab. 2019 Jul 26;32(7):767-774. doi: 10.1515/jpem-2019-0075. PubMed 31211689 ↗
  • Committee on Fetus and Newborn; Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011 Mar;127(3):575-9. doi: 10.1542/peds.2010-3851. Epub 2011 Feb 28. PubMed 21357346 ↗
  • Quarta A, Iannucci D, Guarino M, Blasetti A, Chiarelli F. Hypoglycemia in Children: Major Endocrine-Metabolic Causes and Novel Therapeutic Perspectives. Nutrients. 2023 Aug 11;15(16):3544. doi: 10.3390/nu15163544. PubMed 37630734 ↗
  • Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Rozance PJ, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI; Pediatric Endocrine Society. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr. 2015 Aug;167(2):238-45. doi: 10.1016/j.jpeds.2015.03.057. Epub 2015 May 6. No abstract available. PubMed 25957977 ↗
  • Guemes M, Rahman SA, Hussain K. What is a normal blood glucose? Arch Dis Child. 2016 Jun;101(6):569-574. doi: 10.1136/archdischild-2015-308336. Epub 2015 Sep 14. PubMed 26369574 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Jan 2028, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 16, 2026
StartEst.
Apr 15, 2026
Primary completionEst.
Jan 15, 2028
CompletionEst.
Apr 15, 2028
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07533318
Lead sponsor
Sohag University
Responsible party
Menatalla Moamen Ramadan Mohamed (Assistant lecturer of pediatrics, Sohag University) — Principal investigator
First posted
Apr 16, 2026
Start date
Apr 15, 2026 (estimated)
Primary completion
Jan 15, 2028 (estimated)
Completion
Apr 15, 2028 (estimated)
Last update
Apr 16, 2026

Study contacts

Menatalla Moamen Ramadan Mohamed
Contact
menaamoamen@med.sohag.edu.eg
+201062475212

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion